Self-reported @entity170 prevention in inhaled XXXX users in community pharmacy setting.

@entity1 @entity174 @entity170 @entity228 @entity460 @entity1030 @entity560 @entity288
OBJECTIVES: The use of inhaled @entity288 is the standard maintenance therapy in asthma therapy and as adjunct therapy in moderate to severe @entity1030 . A dose-related increase in @entity174 risk is associated with inhaled @entity228 use; there is an inverse relationship between bone mineral density and duration and cumulative dose of inhaled @entity228 . Adequate intake of @entity460 and @entity560 are cornerstones of @entity170 prevention. The objectives are to assess whether the proportion of @entity1 receiving inhaled @entity288 are taking @entity460 and @entity560 ; the association between long-term inhaled @entity228 use and abnormal bone mineral density or @entity174 ; and how many qualified @entity1 received bone mineral density scans. METHODS: @entity1 who filled a prescription for inhaled @entity288 at selected community pharmacies across Alberta were recruited for a survey of their @entity170 prevention activities. RESULTS: A total of 256 @entity1 from 12 community pharmacies were included. The average age was 60        17.4   years with 65% female. There were 21%, 51%, and 28% of @entity1 on high, medium, and low dose inhaled @entity288 , respectively. Only 17% of @entity1 >50   years old received recommended @entity460 and @entity560 supplementation and 87 (73%) of the qualified @entity1 received bone mineral density scan. CONCLUSION: @entity170 prevention in inhaled @entity228 users is currently poorly addressed. More promotion is needed to raise pharmacist awareness of the risks of inhaled @entity288 .
